Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
https://doi.org/10.17650/2222-1468-2018-8-1-24-27
Abstract
Radioiodine therapy of metastatic differentiated thyroid cancer is a highly effective method of treatment which makes it possible to achieve the complete cure of the majority of patients, however in some cases radioiodine refractory type develops, it leads to significant deterioration in overall and relapse-free survival. The article presents own experience of the therapy of radioiodine refractory thyroid cancer by the nexavar (sorafenib).
About the Authors
E. B. Vasil’eva
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
A. V. Vazhenin
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine; South Ural State Medical University, Ministry of Health of Russia.
Russian Federation
64 Vorovskogo St., Chelyabinsk 454092.
Russian Federation
64 Vorovskogo St., Chelyabinsk 454092.
T. M. Geliashvili
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
N. V. Fadeeva
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
A. V. Garev
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
A. O. Guz’
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
Russian Federation
42 Blyukhera St., Chelyabinsk 454087.
References
1. Исаев П.А., Румянцев П.О., Полькин В.В. и др. Клинические случаи эффективности Нексавара (сорафениба) после терапии 131-I у больных метастатическим дифференцированным раком щитовидной железы. Опухоли головы и шеи 2014;(2):46–50. [Isaev P.A., Rumyantsev P.O., Polkin V.V. et al. Clinical expe rience of Nexavar (sorafenib) application in patients with metastatic differentiated thyroid cancer resistant to therapy 131-I. Opukholi golovy i shei = Head and Neck Tumors 2014;(2):46–50. (In Russ.)].
2. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI: 10.1210/jc.2005-1322.
3. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI: 10.1016/ S0140-6736(14)60421-9.
4. Гелиашвили Т.М., Важенин А.В., Васильева Е.Б. Опыт работы отделения радионуклидной терапии в ГБУЗ «Челябинский областной клинический онкологический диспансер». В сб.: Онкология – XXI век: материалы XXI Международной научной конфе
5. ренции по онкологии. Тбилиси, 2017. С. 60–63. [Geliashvili T.M., Vazhenin A.V., Vasil’eva E.B. Work experience of the Department of Radionuclide Therapy at the State Budgetary Healthcare Institution Chelyabinsk Regional Clinical Oncologic Dispensary. In: Oncology – XXI century: Processing of the XXI International Oncology Scientific Conference. Tbilisi, 2017. Pр. 60–63. (In Russ.)].
6. Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8. DOI: 10.1016/S22138587(13)70215-8.
Review
For citations:
Vasil’eva E.B., Vazhenin A.V., Geliashvili T.M., Fadeeva N.V., Garev A.V., Guz’ A.O. Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. Head and Neck Tumors (HNT). 2018;8(1):24-27. (In Russ.) https://doi.org/10.17650/2222-1468-2018-8-1-24-27
Views:
811
Email this article 